Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Zanubrutinib in Japanese Patients With Mature B-Cell Malignancies

NCT04172246 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04172246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04172246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Zanubrutinib in Japanese Patients With Mature B-Cell Malignancies
Lead sponsor
BeiGene
Phase
Phase 1/2
Overall status
Completed
Start date
January 29, 2020
Completion date
June 30, 2025
Enrollment
55 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

mature b-cell malignancies